|
|
|
| Tandem Expression, Purification and Bioactivity Characterization of Conotoxin MrIA |
| ZHU Xiao-peng1,2,3, ZHANG Ya-ning1, YU Jin-peng1, LI Xiao-dan1, LUO Su-lan1,2, ZHANGSUN Dong-ting1,2 |
1. Key Laboratory of Tropical Biological Resources, Ministry of Education, Key Laboratory for Marine Drugs of Haikou, Hainan University, Haikou 570228, China;
2. College of Marine Science, Hainan University, Haikou 570228, China;
3. College of Horticulture and Landscapes, Hainan University, Haikou 570228, China |
|
|
|
Abstract CTxs are small peptides which specific target variety of voltage-gated ion channels and membrane receptor. Conotoxins are important tools for the study of receptors structure and function and their related diseases. MrIA is a T-superfamily conotoxin which was entering clinical research for analgesia. The traditional methods to acquire conotoxin are chemical synthesis, while these methods are cost-consuming but low yields. Tandem repeats of mria gene fragment were constructed and ligated with prokaryotic expression vector. The rMrIA was expressed successfully in E.coli. 95% purity rMrIA were obtained by CNBr cleavage and purification, 30mg rMrIA could be obtained from 1L media eventually. Mice hot plate test showed that rMrIA had good analgesic activity. An effective method to obtain large quantities of MrIA and a model for other small conotoxins expression were provided.
|
|
Received: 09 October 2015
Published: 15 February 2016
|
|
|
|
|
| [1] Norton R S, Olivera B M. Conotoxins down under. Toxicon,2006,48(7):780-798.
[2] Olivera B M. Conus peptides:biodiversity-based discovery and exogenomics. J Biol Chem,2006,281(42):31173-31177.
[3] Olivera B M. E.E.Just Lecture,1996.Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. Mol Biol Cell,1997,8(11):2101-2109.
[4] Davis J, Jones A, Lewis R J. Remarkable inter-and intra-species complexity of conotoxins revealed by LC/MS. Peptides,2009,30(7):1222-1227.
[5] Olivera B M, Rivier J, Clark C, et al.Diversity of Conus neuropeptides. Science,1990,249(4966):257-263.
[6] Robinson S D, Norton R S. Conotoxin gene superfamilies. Mar Drugs,2014,12(12):6058-6101.
[7] McIntosh J M, Corpuz G O, Layer R T, et al. Isolation and characterization of a novel conus peptide with apparent antinociceptive activity. J Biol Chem,2000,275(42):32391-32397.
[8] Balaji R A, Ohtake A, Sato K,et al. lambda-conotoxins, a new family of conotoxins with unique disulfide pattern and protein folding. Isolation and characterization from the venom of Conus marmoreus. J Biol Chem,2000,275(50):39516-39522.
[9] Goddard A W, Ball S G, Martinez J, et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety,2010,27(4):339-350.
[10] Nielsen C K, Lewis R J, Alewood D, et al. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain,2005,118(1-2):112-124.
[11] Lewis R J, Dutertre S, Vetter I, et al. Conus venom peptide pharmacology. Pharmacol Rev,2012,64(2):259-298.
[12] Casarrubea M, Sorbera F, Santangelo A, et al. The effects of diazepam on the behavioral structure of the rat's response to pain in the hot-plate test: anxiolysis vs. pain modulation. Neuropharmacology,2012,63(2):310-321.
[13] Lewis R J. Discovery and development of the χ-conopeptide class of analgesic peptides. Toxicon,2012,59(4):524-528.
[14] Brust A, Palant E, Croker D E, et al. chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. J Med Chem,2009,52(22):6991-7002.
[15] Kumar G S, Ramasamy P, Sikdar S K, et al. Overexpression, purification, and pharmacological activity of a biosynthetically derived conopeptide. Biochem Biophys Res Commun,2005,335(3):965-972.
[16] Bruce C, Fitches E C, Chougule N, et al. Recombinant conotoxin, TxVIA, produced in yeast has insecticidal activity. Toxicon,2011,58(1):93-100.
[17] Hruby V J. Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov,2002,1(11):847-858.
[18] Sharpe I A, Palant E, Schroeder C I,et al. Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship. J Biol Chem,2003,278(41):40317-40323.
[19] Kuliopulos A, Walsh C T. Production, purification, and cleavage of tandem repeats of recombinant peptides. J Am Chem Soc,1994,116(11):4599-4607.
[20] Hwang P M, Pan J S, Sykes B D.Targeted expression, purification, and cleavage of fusion proteins from inclusion bodies in Escherichia coli. FEBS Lett,2014,588(2):247-252. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
